Denmark· DK-28103566703
Certican
A everolimus product containing everolimus, registered in Denmark by Novartis Healthcare A/S. The same ATC class is registered in 9 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Everolimus is registered in 9 of 19 countries.
Countries holding a registration under ATC L04AH02 (everolimus), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 6 of them publish a price we can compare per daily dose
Everolimus · ATC L04AH02
9 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Switzerlandprice
Price per daily dose
What a daily dose of everolimus costs, country by country.
Normalised to the WHO defined daily dose (1.5 mg), the median price runs from $4.19 in United States to $20.09 in Switzerland — a ×4.8 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Everolimus · price per daily dose (1.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$20.09
- ES Spain$15.84
- US United States$4.19 (acquisition cost)
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Everolimus
- Manufacturer
- Novartis Healthcare A/S
- Country
- Denmark (DK)
- ATC code
- L04AH02
- ATC class
- Everolimus
- Defined daily dose
- 1.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28103566703
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
428 interactions on record for everolimus.
Graded by severity as the source publishes them — 165 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Everolimus · interactions on record
428 records
- 165 severe
- 255 moderate
- 8 minor
Most severe, free to view
- AprepitantA04AD12severe
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L04AH02
Everolimus, as other registers publish it.
- FinlandAderolioSandoz A/S
- FinlandAderolioSandoz A/S
- FinlandAderolioSandoz A/S
- FinlandAderolioSandoz A/S
- CanadaAFINITORNOVARTIS PHARMACEUTICALS CANADA INC
- CanadaAFINITORNOVARTIS PHARMACEUTICALS CANADA INC
- CanadaAFINITORNOVARTIS PHARMACEUTICALS CANADA INC
- CanadaAFINITOR DISPERZNOVARTIS PHARMACEUTICALS CANADA INC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c03bd82f-dea6-442c-98d2-8c1b5aa5ab6c GET /v1/drugs/c03bd82f-dea6-442c-98d2-8c1b5aa5ab6c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "tabletter",
"source": "dkma",
"strength": "1 mg",
"auth_role": "CMS",
"dk_drugid": "28103566703",
"substance": "Everolimus",
"auth_procedure": "MRP",
"in_medicinpriser": false,
"registration_date_serial": "38020"
}See everything about everolimus.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.